Monte Rosa Therapeutics (GLUE) Free Cash Flow (2020 - 2026)

Monte Rosa Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$39.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 14.32% year-over-year to -$39.2 million; the TTM figure through Mar 2026 stood at -$16.4 million (down 146.43% YoY), while the FY2025 annual figure was -$22.9 million, down 154.71% from the prior year.
• Free Cash Flow was -$39.2 million for Q1 2026 at Monte Rosa Therapeutics, roughly flat from -$39.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $132.7 million in Q4 2024 to a low of -$45.8 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$10.0 million across 5 years, with a median of -$29.1 million in 2022.
• Biggest YoY gain for Free Cash Flow was 566.4% in 2025; the steepest drop was 129.57% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$32.1 million in 2022, then soared by 245.54% to $46.7 million in 2023, then soared by 183.81% to $132.7 million in 2024, then tumbled by 129.57% to -$39.2 million in 2025, then declined by 0.02% to -$39.2 million in 2026.
• The last three Free Cash Flow figures came in at -$39.2 million (Q1 2026), -$39.2 million (Q4 2025), and $99.8 million (Q3 2025), per Business Quant data.